Cargando…
The effects of transitioning from immediate release to extended release cysteamine therapy in Norwegian patients with nephropathic cystinosis: a retrospective study
BACKGROUND: Nephropathic cystinosis is a rare lysosomal storage disorder in which accumulation of cystine and formation of crystals particularly impair kidney function and gradually lead to multi-organ dysfunction. Lifelong therapy with the aminothiol cysteamine can delay the development of kidney f...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514171/ https://www.ncbi.nlm.nih.gov/pubmed/37219641 http://dx.doi.org/10.1007/s00467-023-06005-w |
_version_ | 1785108671034818560 |
---|---|
author | Bjerre, Anna Aase, Sonja Amdal Radtke, Maria Siva, Christian Gudmundsdottir, Helga Forsberg, Brita Woldseth, Berit Brackman, Damien |
author_facet | Bjerre, Anna Aase, Sonja Amdal Radtke, Maria Siva, Christian Gudmundsdottir, Helga Forsberg, Brita Woldseth, Berit Brackman, Damien |
author_sort | Bjerre, Anna |
collection | PubMed |
description | BACKGROUND: Nephropathic cystinosis is a rare lysosomal storage disorder in which accumulation of cystine and formation of crystals particularly impair kidney function and gradually lead to multi-organ dysfunction. Lifelong therapy with the aminothiol cysteamine can delay the development of kidney failure and the need for transplant. The purpose of our long-term study was to explore the effects of transitioning from immediate release (IR) to extended release (ER) formulation in Norwegian patients in routine clinical care. METHODS: We retrospectively analysed data on efficacy and safety in 10 paediatric and adult patients. Data were obtained from up to 6 years before and 6 years after transitioning from IR- to ER-cysteamine. RESULTS: Mean white blood cell (WBC) cystine levels remained comparable between the different treatment periods (1.19 versus 1.38 nmol hemicystine/mg protein) although most patients under ER-cysteamine underwent dose reductions. For the non-transplanted patients, the mean estimated glomerular filtration rate (eGFR) change/year was more pronounced during ER-treatment (− 3.39 versus − 6.80 ml/min/1.73 m(2)/year) possibly influenced by individual events, such as tubulointerstitial nephritis and colitis. Growth measured by Z-height score tended to develop positively. Four of seven patients reported improvement of halitosis, one reported unchanged and two reported worsened symptoms. Most adverse drug reactions (ADRs) were of mild severity. One patient developed two serious ADRs and switched back to IR-formulation. CONCLUSIONS: The results from this long-term retrospective study indicate that switching from IR- to ER-cysteamine was feasible and well tolerated under routine clinical practice. ER-cysteamine allowed satisfactory disease control over the long period considered. GRAPHICAL ABSTRACT: [Figure: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00467-023-06005-w. |
format | Online Article Text |
id | pubmed-10514171 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-105141712023-09-23 The effects of transitioning from immediate release to extended release cysteamine therapy in Norwegian patients with nephropathic cystinosis: a retrospective study Bjerre, Anna Aase, Sonja Amdal Radtke, Maria Siva, Christian Gudmundsdottir, Helga Forsberg, Brita Woldseth, Berit Brackman, Damien Pediatr Nephrol Original Article BACKGROUND: Nephropathic cystinosis is a rare lysosomal storage disorder in which accumulation of cystine and formation of crystals particularly impair kidney function and gradually lead to multi-organ dysfunction. Lifelong therapy with the aminothiol cysteamine can delay the development of kidney failure and the need for transplant. The purpose of our long-term study was to explore the effects of transitioning from immediate release (IR) to extended release (ER) formulation in Norwegian patients in routine clinical care. METHODS: We retrospectively analysed data on efficacy and safety in 10 paediatric and adult patients. Data were obtained from up to 6 years before and 6 years after transitioning from IR- to ER-cysteamine. RESULTS: Mean white blood cell (WBC) cystine levels remained comparable between the different treatment periods (1.19 versus 1.38 nmol hemicystine/mg protein) although most patients under ER-cysteamine underwent dose reductions. For the non-transplanted patients, the mean estimated glomerular filtration rate (eGFR) change/year was more pronounced during ER-treatment (− 3.39 versus − 6.80 ml/min/1.73 m(2)/year) possibly influenced by individual events, such as tubulointerstitial nephritis and colitis. Growth measured by Z-height score tended to develop positively. Four of seven patients reported improvement of halitosis, one reported unchanged and two reported worsened symptoms. Most adverse drug reactions (ADRs) were of mild severity. One patient developed two serious ADRs and switched back to IR-formulation. CONCLUSIONS: The results from this long-term retrospective study indicate that switching from IR- to ER-cysteamine was feasible and well tolerated under routine clinical practice. ER-cysteamine allowed satisfactory disease control over the long period considered. GRAPHICAL ABSTRACT: [Figure: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00467-023-06005-w. Springer Berlin Heidelberg 2023-05-23 2023 /pmc/articles/PMC10514171/ /pubmed/37219641 http://dx.doi.org/10.1007/s00467-023-06005-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Bjerre, Anna Aase, Sonja Amdal Radtke, Maria Siva, Christian Gudmundsdottir, Helga Forsberg, Brita Woldseth, Berit Brackman, Damien The effects of transitioning from immediate release to extended release cysteamine therapy in Norwegian patients with nephropathic cystinosis: a retrospective study |
title | The effects of transitioning from immediate release to extended release cysteamine therapy in Norwegian patients with nephropathic cystinosis: a retrospective study |
title_full | The effects of transitioning from immediate release to extended release cysteamine therapy in Norwegian patients with nephropathic cystinosis: a retrospective study |
title_fullStr | The effects of transitioning from immediate release to extended release cysteamine therapy in Norwegian patients with nephropathic cystinosis: a retrospective study |
title_full_unstemmed | The effects of transitioning from immediate release to extended release cysteamine therapy in Norwegian patients with nephropathic cystinosis: a retrospective study |
title_short | The effects of transitioning from immediate release to extended release cysteamine therapy in Norwegian patients with nephropathic cystinosis: a retrospective study |
title_sort | effects of transitioning from immediate release to extended release cysteamine therapy in norwegian patients with nephropathic cystinosis: a retrospective study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514171/ https://www.ncbi.nlm.nih.gov/pubmed/37219641 http://dx.doi.org/10.1007/s00467-023-06005-w |
work_keys_str_mv | AT bjerreanna theeffectsoftransitioningfromimmediatereleasetoextendedreleasecysteaminetherapyinnorwegianpatientswithnephropathiccystinosisaretrospectivestudy AT aasesonjaamdal theeffectsoftransitioningfromimmediatereleasetoextendedreleasecysteaminetherapyinnorwegianpatientswithnephropathiccystinosisaretrospectivestudy AT radtkemaria theeffectsoftransitioningfromimmediatereleasetoextendedreleasecysteaminetherapyinnorwegianpatientswithnephropathiccystinosisaretrospectivestudy AT sivachristian theeffectsoftransitioningfromimmediatereleasetoextendedreleasecysteaminetherapyinnorwegianpatientswithnephropathiccystinosisaretrospectivestudy AT gudmundsdottirhelga theeffectsoftransitioningfromimmediatereleasetoextendedreleasecysteaminetherapyinnorwegianpatientswithnephropathiccystinosisaretrospectivestudy AT forsbergbrita theeffectsoftransitioningfromimmediatereleasetoextendedreleasecysteaminetherapyinnorwegianpatientswithnephropathiccystinosisaretrospectivestudy AT woldsethberit theeffectsoftransitioningfromimmediatereleasetoextendedreleasecysteaminetherapyinnorwegianpatientswithnephropathiccystinosisaretrospectivestudy AT brackmandamien theeffectsoftransitioningfromimmediatereleasetoextendedreleasecysteaminetherapyinnorwegianpatientswithnephropathiccystinosisaretrospectivestudy AT bjerreanna effectsoftransitioningfromimmediatereleasetoextendedreleasecysteaminetherapyinnorwegianpatientswithnephropathiccystinosisaretrospectivestudy AT aasesonjaamdal effectsoftransitioningfromimmediatereleasetoextendedreleasecysteaminetherapyinnorwegianpatientswithnephropathiccystinosisaretrospectivestudy AT radtkemaria effectsoftransitioningfromimmediatereleasetoextendedreleasecysteaminetherapyinnorwegianpatientswithnephropathiccystinosisaretrospectivestudy AT sivachristian effectsoftransitioningfromimmediatereleasetoextendedreleasecysteaminetherapyinnorwegianpatientswithnephropathiccystinosisaretrospectivestudy AT gudmundsdottirhelga effectsoftransitioningfromimmediatereleasetoextendedreleasecysteaminetherapyinnorwegianpatientswithnephropathiccystinosisaretrospectivestudy AT forsbergbrita effectsoftransitioningfromimmediatereleasetoextendedreleasecysteaminetherapyinnorwegianpatientswithnephropathiccystinosisaretrospectivestudy AT woldsethberit effectsoftransitioningfromimmediatereleasetoextendedreleasecysteaminetherapyinnorwegianpatientswithnephropathiccystinosisaretrospectivestudy AT brackmandamien effectsoftransitioningfromimmediatereleasetoextendedreleasecysteaminetherapyinnorwegianpatientswithnephropathiccystinosisaretrospectivestudy |